Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP982457priorityCriticalpatent/ECSP982457A/en
Publication of ECSP982457ApublicationCriticalpatent/ECSP982457A/en
Organic Low-Molecular-Weight Compounds And Preparation Thereof
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Nuevo producto farmacéutico hidrocloruro de N-[3-[[2-(e,4-dimetoxifenil)etil]amino]propil]-4-nitrobenzamida, caracterizado porque: (i) contiene agua en la proporción de 1,7 a 2,4 equivalentes molares; y/o (ii) tiene un punto de fusión superior a 145oC y/o (iii) da un espectro infrarrojo que contiene picos a 3510, 3342, 3076, 1665, 1598, 1343, 1330, 1216 y 801 cm-1: y/o (iv) da un espectro de resonancia magnética nuclear en estado sólido que contiene desplazamientos químicos como se representa sustancialmente en la tabla I; y/o (v) da un patrón de disfracción en polvo de rayos X (XRPD) sustancialmente como se representa en la tabla II; un procedimiento para preparar dicho compuesto, una composición farmacéutica que comprende dicho compuesto, y el uso de dicho compuesto en medicina.New pharmaceutical product N- [3 - [[2- (e, 4-dimethoxyphenyl) ethyl] amino] propyl] -4-nitrobenzamide, characterized in that: (i) contains water in the proportion of 1.7 to 2, 4 molar equivalents; and / or (ii) has a melting point higher than 145oC and / or (iii) gives an infrared spectrum containing peaks at 3510, 3342, 3076, 1665, 1598, 1343, 1330, 1216 and 801 cm-1: and / or (iv) gives a solid state nuclear magnetic resonance spectrum containing chemical shifts as substantially represented in Table I; and / or (v) gives an X-ray powder scattering pattern (XRPD) substantially as depicted in Table II; a procedure for preparing said compound, a pharmaceutical composition comprising said compound, and the use of said compound in medicine.
ECSP9824571998-03-251998-03-25
NEW PHARMACEUTICAL PRODUCT
ECSP982457A
(en)
Quinazoline derivatives, process for their preparation, pharmaceutical compositions containing the compounds and use of the new and known quinazoline derivatives against proliferative disease
HOMOGENEOUS CRYSTALLINE POLYMORPHES OF N - (3 - ETHYLFENYL) CHLORHYDRATE - 6, 7 - BIS (2 - METOXIETOXI) - 4 QUINAZOLINAMINE; PHARMACEUTICAL COMPOSITIONS FORMULATED WITH SUCH POLYMORPHES; USE OF THE SAME IN THE PREPARATION OF SUCH COMPOSITIONS; PROCESS FOR THE PREPARATION OF POLYMORPH B
Use of paclitaxel stabilized with albumin for the preparation of pharmaceutical compositions treating solid tumors and the pharmaceutical compositions obtained thereby
DERIVATIVES OF QUINOLINA. PROCEDURE FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINE
2'-substituted 1, 1'-biphenyl-2-carbonamides, method for the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds
Biphenyl derivatives, of imidazole and benzimidazole the use thereof, process for the preparation of compounds and pharmaceutical compositions containing them